NCT00793871View on ClinicalTrials.gov

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

April 30, 2014

Study Completion Date

October 31, 2014

Conditions
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Interventions
DRUG

Sunitinib Malate (SU011248)

Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.

Trial Locations (4)

100021

Cancer Institute & Hospital Chinese Academy of Medical Sciences and PUMC, Beijing

100035

Beijing Cancer Hospital, Beijing

100071

307 Hospital of PLA, Beijing

210002

Nanjing Bayi Hospital, Nanjing

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00793871 - Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor | Biotech Hunter | Biotech Hunter